Industry Nets House Victory On Perceived Product Liability Threat
This article was originally published in The Gray Sheet
After two weeks of heavy lobbying, language device companies feared would make them more vulnerable to patient lawsuits was removed June 19 from FDA legislation in the House
You may also be interested in...
Device industry support for the House medical device user fee reauthorization bill is threatened by language that companies say would make them more vulnerable to patient lawsuits
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.